ClinicalTrials.gg
Not yet recruitingNCT07004400RENEW RCTUpdated Jun 4, 2025

A Blinded Randomized Clinical Study of RefluxStop™ Compared With Nissen Fundoplication in the Treatment of GERD

An interventional study of RefluxStop™ implantation and Nissen fundoplication in GERD (Gastroesophageal Reflux Disease), sponsored by Implantica CE Reflux Ltd.. Not yet recruiting at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-04.

Sponsored by Implantica CE Reflux Ltd. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 70 studies in Gastroesophageal Reflux with a site in Germany — 7 open to participants now, 8 under way, none of them phase 3. Gastroesophageal Reflux · Germany.

Planned enrollment
27th of 54
200 · median 180
Started
2025
with 3 others
No phase
14 of 70
4 open now
Registered
66th of 70
by date
Lead sponsor
3 of 70
Implantica CE Reflux Ltd.

Among the 70 studies in Gastroesophageal Reflux with a site in Germany, this one is the 27th largest by planned enrollment of the 54 interventional ones that give a count, is one of 4 that started in 2025, is one of 14 with no phase, and was the 66th registered.

Gastroesophageal Reflux

1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

7 of the 70 studies in Gastroesophageal Reflux with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Gastroesophageal Reflux with a site in Germany, or all of them as a file.
02

Study summary

This study will evaluate if the RefluxStop™ device will treat your acid reflux and improve your symptoms and how it compares to the standard surgical treatment for GERD, the Nissen fundoplication.

Read the detailed description

This study is a post-market prospective, blinded, randomized, multicenter, multi-arm clinical investigation using standard clinical procedures to record data to evaluate the safety and performance of RefluxStop™ compared with standard Nissen fundoplication for the treatment of subjects suffering from GERD.

A randomization will be performed where the Subjects will be blinded as to assigned randomization group.

03

Conditions studied

  • GERD (Gastroesophageal Reflux Disease)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to provide and to participate in the clinical investigation;
  2. Age ≥ 18 years or according to local legal age of adulthood at the location of the test site if older;
  3. Documented GERD present for ≥ 12 months. Typical symptoms are defined as heartburn, which is a burning sensation often presented as a substernal pain;
  4. 24-hour pH monitoring proven GERD with pH measurement, off PPI therapy for at least 7 days prior to testing. (Total distal esophageal pH must be \< 4 for ≥ 4.5% of time during a 24-hour monitoring);
  5. Suitable to undergo general anesthesia and is a suitable laparoscopic surgery candidate as determined by the investigator

Exclusion criteria

Exclusion Criteria:

  1. > 8 cm sliding hernia and paraesophageal hernia; no mesh is allowed;
  2. Manometry verified lack of or moderate or severe weak peristalsis in esophagus with DCI \<300 or pathologic LOS function including hypercontractability, spasm or pathologic nonrelaxing functionality (the latter defined as coordinated swallows in less than 70% of wet swallows or median IRP>15mmHg). Hypercontractability defined as DCI >8'000 or pressure >45 mmHg. Thus, excluding from the study the rare diseases achalasia, scleroderma, and nutcracker esophagus, however, including mild esophageal motility disorder patients with mildly weak peristalsis;
  3. History of bariatric or anti-reflux surgery;
  4. Female subjects who are pregnant or nursing;
  5. Known sensitivity or allergies to silicone materials;
  6. Intraoperative findings determined by the investigator that may result in unfavorable conduct of the clinical investigation procedure (as outlined in the IFU);
  7. Subjects that are unable to comply with the clinical investigation requirements (for example due to major psychiatric disorder or are considered otherwise unsuitable for participation in the clinical investigation according to the investigator's judgement);
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    RefluxStop™ device implantation

    Standard surgical technique for implantation RefluxStop™, as described in the Instructions for Use

    Device: RefluxStop™ implantation

  • Active comparator
    Nissen fundoplication surgery

    Standard surgical technique of Nissen fundoplication

    Procedure: Nissen fundoplication

Interventions

  • DeviceRefluxStop™ implantation

    Standard surgical technique for implantation RefluxStop™, as described in the Instructions for Use

  • ProcedureNissen fundoplication

    Standard surgical technique for Nissen fundoplication

06

What researchers measure

Primary outcomes

  1. Patient Reported Outcomes - Side effects (PROS) evaluation

    Patient Reported Outcomes - Side effects (PROS) evaluation at 6 months, combining the well-established side effects of traditional surgical treatment methods: * Dysphagia - swallowing difficulties; * Odynophagia - pain at swallowing; * Inability to belch and inability to vomit; and * Worsening of gas bloating compared to baseline;

    Time frame: 6 months

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Dec 2026, 16 months later.

Of 34 industry-sponsored interventional studies with no phase under Gastroesophageal Reflux, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 16 months is below that.

Counting every sponsor, half of 228 studies reached it within 32 months; a quarter within 12 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2025
First posted
Jun 4, 2025
StartEst.
Aug 1, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Jun 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07004400
Lead sponsor
Implantica CE Reflux Ltd.
Responsible party
Sponsor
First posted
Jun 4, 2025
Start date
Aug 1, 2025 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Jun 4, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion